MEACO head to become WOC 2012 president

Article

President of the Middle East African Council of Ophthalmology (MEACO), Dr Abdulaziz Al Rajhi, is to become president of the World Ophthalmology Congress (WOC) 2012.

President of the Middle East African Council of Ophthalmology (MEACO), Dr Abdulaziz Al Rajhi, is to become president of the World Ophthalmology Congress (WOC) 2012.

The next WOC, which will be the 33rd in the series, will take place in two years time in Abu Dhabi at its award winning exhibition centre from 16-20 February.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Subscribe Now!
Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
Early intervention is crucial for long-term outcomes in paediatric gene therapy
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Robert Ang, MD, explains why a small-aperture IOL is "not a niche product"
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
ARVO 2025: Ocular and systemic mitochondrial diseases may be key to dementia diagnosis
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
ARVO 2025: Alfredo Sadun, MD, PhD, says "later is better" for some LHON interventions
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Nitish Mehta, MD, provides real-world insights from aflibercept 8 mg for treatment-naive diabetic macular oedema
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
ARVO 2025: Anat Loewenstein, MD, and colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
Sheng Lim, MD, FRCOphth, brings data from the CONCEPT study to the ASCRS meeting
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
A panel discussion on extended treatment intervals in retinal therapy breaks the mold at COPHy 2025
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
How embracing opposition sends clinicians home from COPHy with more useful takeaways
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Angiogenesis 2025: The global forecast for AI-driven home OCT
Related Content
The Agência de vigilância Sanitária (ANVISA) in Brazil. Concept image for pharmaceutical approval, Lucentis ranibizumab biosimilar ranivisio FYB201. Image credit: ©Rmcarvalhobsb – stock.adobe.com

Brazil’s ANVISA grants marketing authorization to Lucentis biosimilar FYB201 (Ranivisio, Formycon/Bioeq AG)

Lynda Charters
June 5th 2025
Article

The biopharmaceutical is the first biosimilar to ranibizumab (Genentech Inc.) approved in Brazil

Higher molar dose and its translation into clinical practice. Led by John Kitchens, MD; Joined by Peter Kaiser, MD

Higher Molar Dose and Its Translation into Clinical Practice

John Kitchens, MD;Peter Kaiser, MD
July 22nd 2024
Podcast
A bridge made from building blocks has an incomplete area. A hand reaches down with the missing block to close the gap. Concept image for age-related macular degeneration therapy and treatment article, IOL implantation and ophthalmology. Image credit: ©patpitchaya – stock.adobe.com

An implantable option bridges the gap for patients with AMD

Federico Badalà, MD
June 4th 2025
Article

Long-term benefits and vision preservation using an extended macular vision IOL

A scientist in a lab coat works at a microscope. On the right-hand side of the image, strands of sequenced DNA. Concept image for genome-wide association study in eye care, pseudodrusen and drusen, age-related macular degeneration, inherited eye ocular disease. ©Mongkolchon – stock.adobe.com

Unveiling genetic distinctions between reticular pseudodrusen and drusen

Roy Schwartz, MD, PhD
June 3rd 2025
Article

Insights from a genome-wide association study identify novel genetic loci

A small icon pinpoints a particular location on a map. Concept image for article titled "pinpointing a first-line treatment for glaucoma." Ophthalmology article, glaucoma laser treatment concept. Image credit: ©Pavlo Vakhrushev – stock.adobe.com

Pinpointing a first-line treatment for glaucoma

José María Martínez de la Casa, MD
June 3rd 2025
Article

Laser surgery is an appropriate adjunctive therapy across the continuum of glaucoma care, as well as a safe option for patients who also have cataracts and other complicating factors

A person types on a computer. An AI brain is over the screen. Concept image for artificial intelligence, therapy planning assistant system, TPS, Europe, CE mark. Image credit: ©New Africa – stock.adobe.com

EU issues CE mark for AI therapy planning assistant from deepeye Medical

Jordana Joy
June 2nd 2025
Article

The therapy planning support tool has been trained on thousands of patient cases from more than 200 retina centres throughout Europe

© 2025 MJH Life Sciences

All rights reserved.